Matches in Wikidata for { <http://www.wikidata.org/entity/Q59395346> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- Q59395346 description "artículu científicu espublizáu en mayu de 2017" @default.
- Q59395346 description "im Mai 2017 veröffentlichter wissenschaftlicher Artikel" @default.
- Q59395346 description "scientific article published on 05 May 2017" @default.
- Q59395346 description "wetenschappelijk artikel" @default.
- Q59395346 description "наукова стаття, опублікована в травні 2017" @default.
- Q59395346 name "Corrigendum to “Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial” [Vacci" @default.
- Q59395346 name "Corrigendum to “Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial” [Vacci" @default.
- Q59395346 type Item @default.
- Q59395346 label "Corrigendum to “Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial” [Vacci" @default.
- Q59395346 label "Corrigendum to “Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial” [Vacci" @default.
- Q59395346 prefLabel "Corrigendum to “Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial” [Vacci" @default.
- Q59395346 prefLabel "Corrigendum to “Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial” [Vacci" @default.
- Q59395346 P1433 Q59395346-67EDCA89-39F9-451E-8FC2-2373C74A6962 @default.
- Q59395346 P1476 Q59395346-601E14FA-6210-4432-81F3-8BAB4E9EE2D1 @default.
- Q59395346 P2093 Q59395346-28D3C78E-7116-4BB8-AFF7-C701EF23C678 @default.
- Q59395346 P2093 Q59395346-AD31BA28-4A1E-4A15-B5EC-41A4D069FA17 @default.
- Q59395346 P2093 Q59395346-CE4CBD4E-AC49-4B56-AA5A-7559F811CBE2 @default.
- Q59395346 P2093 Q59395346-D413AA8C-9FAF-4219-AEE3-9E348387001F @default.
- Q59395346 P2093 Q59395346-DCD2AC3C-7106-40E1-9031-844C68B232CF @default.
- Q59395346 P2093 Q59395346-F13BB087-B2ED-4083-8E13-82F5FC80AC8B @default.
- Q59395346 P304 Q59395346-7A6585F6-78F3-462A-8326-BEE95C1F0370 @default.
- Q59395346 P31 Q59395346-0341ADFE-A2B7-49D3-9D65-E6F97B5782B5 @default.
- Q59395346 P31 Q59395346-99B004C8-F14E-417A-BBE4-560AF7D85748 @default.
- Q59395346 P356 Q59395346-4C8B1D60-1905-4D87-B5A8-579759B674DE @default.
- Q59395346 P407 Q59395346-EAB65EA3-51D2-4C24-A619-92FBA6B48770 @default.
- Q59395346 P433 Q59395346-E1547B22-7624-48F0-9FC6-55D7D9AD2C80 @default.
- Q59395346 P478 Q59395346-954747AC-3DC5-47EC-ABE5-F2D07E9BEB36 @default.
- Q59395346 P50 Q59395346-3E26A9D4-DECF-4519-9CAA-DB1FD91AE171 @default.
- Q59395346 P50 Q59395346-5120693C-7FC3-4A32-AFFF-D0E646753020 @default.
- Q59395346 P50 Q59395346-66D8AE08-A108-4430-B830-293A5E0AB094 @default.
- Q59395346 P50 Q59395346-68DA44E4-F6C4-4BA4-9825-F73FE469CE33 @default.
- Q59395346 P50 Q59395346-B8DF4764-3BAE-4C73-A4A5-24AB8A74A179 @default.
- Q59395346 P50 Q59395346-D92C319A-F7E2-4435-B72B-E9B6A7E2D0EF @default.
- Q59395346 P50 Q59395346-E7D541ED-D23C-400C-92D2-385E07525343 @default.
- Q59395346 P50 Q59395346-F6313406-53B0-400C-8525-F9EB9C92EB69 @default.
- Q59395346 P50 Q59395346-F83AB587-F3A2-4E72-B37B-26D1944B61B9 @default.
- Q59395346 P577 Q59395346-17A927A5-15D6-4A47-B9A1-3F005A5EBB8B @default.
- Q59395346 P698 Q59395346-32834293-00EA-4AF7-90EA-1D6A662058B3 @default.
- Q59395346 P921 Q59395346-1D2B746F-7420-4E90-8DD1-4546053DB968 @default.
- Q59395346 P921 Q59395346-582963F1-CC7B-4F31-BF53-A2A4EAA31EDB @default.
- Q59395346 P921 Q59395346-9CA517C6-97D4-4C87-AD91-0EA4CEBAD6CD @default.
- Q59395346 P921 Q59395346-EB05C07E-6F45-4C77-A24B-9091C11A5550 @default.
- Q59395346 P356 J.VACCINE.2017.04.081 @default.
- Q59395346 P698 28483197 @default.
- Q59395346 P1433 Q7907941 @default.
- Q59395346 P1476 "Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]" @default.
- Q59395346 P2093 "Adam Finn" @default.
- Q59395346 P2093 "Adefowope Odueyungbo" @default.
- Q59395346 P2093 "European Men B Vaccine Study Group" @default.
- Q59395346 P2093 "Gianni Bona" @default.
- Q59395346 P2093 "Peter Dull" @default.
- Q59395346 P2093 "Sena Jawad" @default.
- Q59395346 P304 "3279" @default.
- Q59395346 P31 Q13442814 @default.
- Q59395346 P31 Q1348305 @default.
- Q59395346 P356 "10.1016/J.VACCINE.2017.04.081" @default.
- Q59395346 P407 Q1860 @default.
- Q59395346 P433 "24" @default.
- Q59395346 P478 "35" @default.
- Q59395346 P50 Q17277123 @default.
- Q59395346 P50 Q24239756 @default.
- Q59395346 P50 Q38641991 @default.
- Q59395346 P50 Q42688630 @default.
- Q59395346 P50 Q55456266 @default.
- Q59395346 P50 Q58479944 @default.
- Q59395346 P50 Q61163339 @default.
- Q59395346 P50 Q64861148 @default.
- Q59395346 P50 Q91463200 @default.
- Q59395346 P577 "2017-05-05T00:00:00Z" @default.
- Q59395346 P698 "28483197" @default.
- Q59395346 P921 Q18123741 @default.
- Q59395346 P921 Q3523816 @default.
- Q59395346 P921 Q42824827 @default.
- Q59395346 P921 Q50608368 @default.